Articles

IKS Health Announces $557M TruBridge Acquisition

Inventurus Knowledge Solutions U.S. subsidiary IKS Health has entered a definitive agreement to acquire 100% of TruBridge in a $557 million enterprise value deal, backed by a $600 million debt facility.

The acquisition combines TruBridge’s EHR and revenue cycle management services with IKS Health’s care enablement platform, with a focus on supporting rural hospitals. The transaction is expected to close in Q2 FY27.

Inventurus Knowledge Solutions has announced a major strategic acquisition through its U.S. subsidiary IKS Health, which has entered into a definitive agreement to acquire 100% of TruBridge. Disclosed under Regulation 30 of SEBI regulations on April 23, 2026, the deal marks a significant step in the company’s broader growth and expansion strategy.

Transaction Highlights
The acquisition represents a significant investment in the healthcare technology sector, with IKS Health planning to take TruBridge private through a comprehensive buyout transaction.

Deal Metric Details
Total Enterprise Value $557M
Equity Value $427M
Debt Assumed $130M
Financing Structure $600M debt facility
Interest Terms SOFR +275 bps (reducing to 175 bps)
Estimated Leverage Ratio Approximately 3X EBITDA

TruBridge Company Profile
TruBridge operates as a fully integrated Revenue Cycle Management (RCM) and Electronic Health Records (EHR) provider, primarily serving small to mid-sized hospitals and rural healthcare facilities across the United States.

Business Segment Revenue (USD Million) Key Highlights
EHR Solutions $126M Approximately 1,500 clients
RCM Services $221M Approximately 3,700 employees
Total Revenue $347M 6% CAGR (2020–2025)
Adjusted EBITDA $69M 10% CAGR (2020–2025)

Strategic Rationale and Market Position
The acquisition supports IKS Health vision of building an integrated healthcare operating system that combines a System of Record (EHR) with a System of Action powered by AI driven care enablement. TruBridge adds a strong presence in rural hospitals, including significant penetration in facilities with fewer than 50 beds and broad reach across rural healthcare providers.

Financial Impact and Timeline
The transaction is expected to be accretive to PAT and EPS in FY27, with the combined organization projected to deliver 26% pro forma adjusted EBITDA. The deal also includes anticipated efficiencies through the elimination of $9.4 million in ESOP related costs and the removal of select non recurring public company expenses.

Timeline Milestone Projected Timing
Definitive Agreement Signed April 23, 2026
Pre Closing Period 90 to 120 days
Expected Transaction Close Q2 FY27
Integration Timeline 4 to 5 quarters after closing

The acquisition will be financed through a five year debt facility, with initial interest costs set at SOFR plus 275 basis points, decreasing to 175 basis points as leverage declines. The company expects to maintain leverage at approximately 3x EBITDA for the combined entity.